Skip Nav Destination
Issues
1 January 2015
-
Cover Image
Cover Image
The cover shows the results of an unsupervised two-dimensional hierarchical clustering analysis of the 5,000 most variable genes classifying breast tumors into ER+, HER2+, or triple-negative (ER−, PR−, HER2−) subtypes. The analysis was performed on 800 breast tumors obtained from the Karolinska Institutet, Sweden. The RAS gene expression signature was high in the triple-negative subtype and low in the ER+ subtype. For details, see the article by Di Cosimo and colleagues on page 49 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR 20th Anniversary Commentary
CCR Translations
CCR New Strategies
Molecular Pathways
Cancer Therapy: Clinical
Author Choice
Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Joseph A. Califano; Zubair Khan; Kimberly A. Noonan; Lakshmi Rudraraju; Zhe Zhang; Hao Wang; Steven Goodman; Christine G. Gourin; Patrick K. Ha; Carole Fakhry; John Saunders; Marshall Levine; Mei Tang; Geoffrey Neuner; Jeremy D. Richmon; Ray Blanco; Nishant Agrawal; Wayne M. Koch; Shanthi Marur; Donald T. Weed; Paolo Serafini; Ivan Borrello
Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Donald T. Weed; Jennifer L. Vella; Isildinha M. Reis; Adriana C. De la fuente; Carmen Gomez; Zoukaa Sargi; Ronen Nazarian; Joseph Califano; Ivan Borrello; Paolo Serafini
Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
Serena Di Cosimo; Sriram Sathyanarayanan; Johanna C. Bendell; Andrés Cervantes; Mark N. Stein; Irene Braña; Desamparados Roda; Brian B. Haines; Theresa Zhang; Christopher G. Winter; Sharda Jha; Youyuan Xu; Jason Frazier; Richard A. Klinghoffer; Ann Leighton-Swayze; Yang Song; Scot Ebbinghaus; José Baselga
Author Choice
A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014
Wells A. Messersmith; Geoffrey I. Shapiro; James M. Cleary; Antonio Jimeno; Arvind Dasari; Bo Huang; M. Naveed Shaik; Rossano Cesari; Xianxian Zheng; Jennifer M. Reynolds; Patricia A. English; Karen R. McLachlan; Kenneth A. Kern; Patricia M. LoRusso
A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
Kim A. Reiss; Joseph M. Herman; Marianna Zahurak; Anthony Brade; Laura A. Dawson; Angela Scardina; Caitlin Joffe; Emily Petito; Amy Hacker-Prietz; Robert J. Kinders; Lihua Wang; Alice Chen; Sarah Temkin; Naomi Horiba; Lillian L. Siu; Nilofer S. Azad
First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
Debashis Sarker; Joo Ern Ang; Richard Baird; Rebecca Kristeleit; Krunal Shah; Victor Moreno; Paul A. Clarke; Florence I. Raynaud; Gallia Levy; Joseph A. Ware; Kathryn Mazina; Ray Lin; Jenny Wu; Jill Fredrickson; Jill M. Spoerke; Mark R. Lackner; Yibing Yan; Lori S. Friedman; Stan B. Kaye; Mika K. Derynck; Paul Workman; Johann S. de Bono
Personalized Medicine and Imaging
Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessment of Antiangiogenic Treatment Effects in Multiple Myeloma
Maximilian Merz; Judith Ritsch; Christina Kunz; Barbara Wagner; Sandra Sauer; Dirk Hose; Thomas Moehler; Stefan Delorme; Hartmut Goldschmidt; Christian Zechmann; Jens Hillengass
Cancer Therapy: Preclinical
Author Choice
Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
Hirdesh Uppal; Estelle Doudement; Kaushiki Mahapatra; Walter C. Darbonne; Daniela Bumbaca; Ben-Quan Shen; Xiaoyan Du; Ola Saad; Kristin Bowles; Steve Olsen; Gail D. Lewis Phillips; Dylan Hartley; Mark X. Sliwkowski; Sandhya Girish; Donna Dambach; Vanitha Ramakrishnan
The Novel IKK2 Inhibitor LY2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of NF-κB
Changchun Deng; Mark Lipstein; Richard Rodriguez; Xavier O. Jirau Serrano; Christine McIntosh; Wei-Yann Tsai; Andrew S. Wasmuth; Susan Jaken; Owen A. O'Connor
CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin
Clara Guerzoni; Valentina Fiori; Mario Terracciano; Maria Cristina Manara; Diego Moricoli; Michela Pasello; Marika Sciandra; Giordano Nicoletti; Mara Gellini; Sabrina Dominici; Claudia Chiodoni; Pier Maria Fornasari; Pier-Luigi Lollini; Mario P. Colombo; Piero Picci; Maurizio Cianfriglia; Mauro Magnani; Katia Scotlandi
Biology of Human Tumors
Author Choice
Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma
Pedram Gerami; Robert W. Cook; Jeff Wilkinson; Maria C. Russell; Navneet Dhillon; Rodabe N. Amaria; Rene Gonzalez; Stephen Lyle; Clare E. Johnson; Kristen M. Oelschlager; Gilchrist L. Jackson; Anthony J. Greisinger; Derek Maetzold; Keith A. Delman; David H. Lawson; John F. Stone
Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups
Diana M. Merino; Adam Shlien; Anita Villani; Malgorzata Pienkowska; Stephen Mack; Vijay Ramaswamy; David Shih; Ruth Tatevossian; Ana Novokmet; Sanaa Choufani; Rina Dvir; Myran Ben-Arush; Brent T. Harris; Eugene I. Hwang; Rishi Lulla; Stefan M. Pfister; Maria Isabel Achatz; Nada Jabado; Jonathan L. Finlay; Rosanna Weksberg; Eric Bouffet; Cynthia Hawkins; Michael D. Taylor; Uri Tabori; David W. Ellison; Richard J. Gilbertson; David Malkin
The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling
Chi-Pang Wen; Fanmao Zhang; Dong Liang; Christopher Wen; Jian Gu; Heath Skinner; Wong-Ho Chow; Yuanqing Ye; Xia Pu; Michelle A.T. Hildebrandt; Maosheng Huang; Chien-Hua Chen; Chao Agnes Hsiung; Min Kuang Tsai; Chwen Keng Tsao; Scott M. Lippman; Xifeng Wu
Activation of IL6/IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT4/NANOG Expression
Te-Sheng Chang; Yu-Chih Wu; Ching-Chi Chi; Wei-Chi Su; Pey-Jium Chang; Kam-Fai Lee; Tao-Hsin Tung; Jui Wang; Jun-Jen Liu; Shui-Yi Tung; Liang-Mou Kuo; Hong-Nerng Ho; Thai-Yen Ling; Yen-Hua Huang
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.